Skip to main content

Table 1 Baseline characteristics

From: Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study

 

All (n = 373)

Men (n = 170)

Women (n = 203)

Case of AF (n, %)

88 (23.6)

46 (27.1)

42 (20.7)

Age (years)

64.0 (5.9)

64.1 (6.1)

64.0 (5.7)

Current smoking (n, %)

85 (22.8)

45 (26.5)

40 (19.7)

History of diabetes (n, %)

32 (8.6)

18 (10.6)

14 (6.9)

History of coronary events (n, %)

8 (2.1)

5 (2.9)

3 (1.5)

History of heart failure (n, %)

2 (0.5)

1 (0.6)

1 (0.5)

Anti-hypertensive medication (n, %)

95 (25.5)

38 (22.4)

57 (28.1)

Systolic blood pressure (mmHg)

143.6 (18.5)

145.2 (18.6)

142.3 (18.3)

Diastolic blood pressure (mmHg)

88.3 (9.6)

90.3 (9.6)

86.6 (9.3)

Height (cm; n = 372)

169.0 (9.4)

176.3 (6.9)

162.8 (6.3)

Weight (kg; n = 372)

77.3 (13.2)

83.9 (12.2)

71.8 (11.4)

HOMA-IR (n = 366)

2.54 (1.83)

2.75 (2.03)

2.36 (1.64)

LDL (mmol/l; n = 372)

3.72 (0.83)

3.67 (0.76)

3.76 (0.89)

NT-proBNP (pg/ml)

41.84 (100.73)

53.22 (128.35)

32.32 (68.56)

Troponin T (pg/ml)

1.14 (1.40)

1.46 (1.66)

0.88 (1.07)

CHARGE-AF risk score (n = 372)

12.01 (0.75)

12.26 (0.73)

11.81 (0.71)

  1. Values are presented as mean (SD) or n (%)
  2. AF atrial fibrillation, HOMA-IR homeostasis model assessment of insulin resistance, LDL low-density lipoprotein, NT-proBNP N terminal pro B type natriuretic peptide